Mar 19, 2019 / 08:30PM GMT
Hartaj Singh - Oppenheimer & Co. - Analyst
Hey, everybody. Thanks for coming over here. This is the last session for the day today. So we have Sunesis, which is a Company I have known for a very long period of time and the CFO of the Company. I am going to give a little inside joke about Willie, which is that he is the true unicorn here at the Oppenheimer healthcare conference today, because he's a true (inaudible). And as you know, that market cap should be bigger than just about any other market cap out there. With that I will hand it off to Willie.
Willie Quinn - Sunesis Pharmaceuticals, Inc. - CFO & SVP, Finance & Corporate Development
Thank you, Hartaj. So I'm going to give you an update on Sunesis today. I will be making some forward-looking statements, so please consult our regulatory filings for risk factors and more details.
Sunesis has a pipeline of kinase inhibitors and I joined the Company a little more than a year ago and for me this is what attracted me to Sunesis. They have some very interesting products. I'll spend most of my
Sunesis Pharmaceuticals Inc at Oppenheimer Healthcare Conference Transcript
Mar 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers